Impact Biomedical (IBO) Revenue (2022 - 2026)
Impact Biomedical (IBO) posted Revenue of $7000.0 for Q1 2026, down 61.11% on a QoQ basis from $18000.0 in Q3 2025.
Impact Biomedical (IBO) Revenue (2022 - 2026) Analysis & Trends
Impact Biomedical's Revenue history runs 3 years deep, the most recent figure standing at $7000.0 for Q1 2026.
- Quarterly Revenue changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY) and the FY2022 annual result came in at $50000.0, changed N/A from the prior year.
- Revenue was $7000.0 for Q1 2026 at Impact Biomedical, down from $18000.0 in the prior quarter.
- Across five years, Revenue topped out at $50000.0 in Q2 2022 and bottomed at $7000.0 in Q2 2025.
- A 3-year average of $20500.0 and a median of $12500.0 in 2025 frame the typical range for Revenue.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.51 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2022 | 50,000.00 |